🏢 官网IRAGENQwen · 实盘不做把握 1/10不做原因:不是事件
北京时间·🕒 发布 08-31 19:30:00·⟳ 抓取 08-31 19:39:40·⚡ 决策 09-01 00:12:25 +4h32m·56.9 天前
Agenus宣布将参加9月两场投资者会议（Cantor全球医疗大会及H.C. Wainwright年度大会）
该公告为标准的投资者会议参与通知（conference participation announcement），仅列明公司高管将出席两场投研会议的时间安排，不含任何新管线数据、财务指引、监管进展、商业合作或管理层变动等可交易信息。此类公告属于最常规的IR例行披露，对股价无方向性影响，不存在可交易的edge。
📄 原文AGEN↗ 原文
Agenus to Participate in Upcoming September Investor Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN) , a leader in immuno-oncology innovation, today announce…
不做 Agenus Inc.（AGEN.US）
例行投资者会议参与公告，不含任何新增可交易信息（无管线数据、无财务更新、无监管进展、无合作/订单），对股价无方向性影响，不存在可交易的edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Agenus于2026-08-31发布投资者会议参与公告，宣布CCO和IR负责人将参加9月Cantor全球医疗大会和H.C. Wainwright年度大会的fireside chat。全文无新管线数据、无财务更新、无监管里程碑、无合作/订单信息，属于最典型的例行IR日程通知。历史上此类公告对股价无系统性影响，不构成可交易催化。结论：不做。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:先例缺失不改变结论，因为事件本身不含任何可交易信息
方向:无先例可用——投资者会议参与公告在学术和实务上均被认为对股价无系统性影响，无需也无法构建有意义的先例样本
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 219 ms
{"result": "search_processed_events:agent query=`agen cantor global healthcare conference | agenus h.c. wainwright conference | agenus investor conference participation september 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、1207 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正
原文全文
展开原文 · 3,143 字
LEXINGTON, Mass.--(BUSINESS WIRE)--
Agenus
Inc. (Nasdaq: AGEN)
, a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will participate in fireside chats and one-on-one investor meetings at two upcoming investor conferences in September.
Cantor Global Healthcare Conference 2026
September 9 -11, 2026; New York, NY
Fireside Chat: Tuesday, September 8, 2026 | 11:30 a.m-12:00 p.m. ET
H.C. Wainwright 28th Annual Global Investment Conference
September 14-16, 2026; New York, NY
Fireside Chat: Monday, September 14, 2026 | 3:00 p.m.-3:30 p.m. ET
An archived recording of the fireside chats will be available for 90 days following each event on the Events & Presentations section of the Agenus investor relations website at
Agenus Inc. - Events
.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit
www.agenusbio.com
or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2025, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investors
917-362-1370 |
investor@agenusbio.com
Media
781-674-4422 |
communications@agenusbio.com
Source: Agenus Inc.
Agenus
Inc. (Nasdaq: AGEN)
, a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will participate in fireside chats and one-on-one investor meetings at two upcoming investor conferences in September.
Cantor Global Healthcare Conference 2026
September 9 -11, 2026; New York, NY
Fireside Chat: Tuesday, September 8, 2026 | 11:30 a.m-12:00 p.m. ET
H.C. Wainwright 28th Annual Global Investment Conference
September 14-16, 2026; New York, NY
Fireside Chat: Monday, September 14, 2026 | 3:00 p.m.-3:30 p.m. ET
An archived recording of the fireside chats will be available for 90 days following each event on the Events & Presentations section of the Agenus investor relations website at
Agenus Inc. - Events
.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit
www.agenusbio.com
or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2025, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investors
917-362-1370 |
investor@agenusbio.com
Media
781-674-4422 |
communications@agenusbio.com
Source: Agenus Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。